Address
10 place de la Joliette
Atrium 10.4 – Etage 6
13002 Marseille, France

News and events

What We Do

Lightcore Technologies provides photonics-based multimodal imaging and analytical solutions for research, life science and clinical care. The developed technologies encompass multiphoton microscopes and flexible endoscopes for fluorescence and label-free imaging such as 2 and 3-photon fluorescence, second (SHG) and third (THG) harmonic generation and coherent Raman processes (CARS and SRS).

Advanced multimodal imaging in a compact, easy to use and affordable package. No installations or alignment by trained personnel is required. Using Lightcore Technologies microscope and flexible endoscope provides immediate access to scientific and industrial relevant data and images through intuitive and easy to use controlled software packages.

Our products

BondXplorer™ microscope

Our BondXplorer™ microscope is the only coherent Raman microscope that can image two chemical bonds (two wavenumbers) at one time, making it an ideal system for virtual histology and several other applications such as metabolic imaging, microplastic screening, pharmaceutical tablet characterization and organoid visualization. All together the BondXplorer microscope has the unique capability to combine chemical imaging with auto-fluorescence/fluorescence imaging and second harmonic generation.

InSplorer™ endoscope

Our InSplorer™ endoscope is a flexible and compact multiphoton endoscope capable of performing multimodal label-free imaging of biological tissues in-vivo. The InSplorer endoscope offers superior imaging performance compared to conventional endoscopes, with micron-scale spatial resolution, penetration depth of several centimeters and low phototoxicity. It targets the markets of biomedical research, life science and clinical care where it can be used for the study of biological tissues in-vivo and ex-vivo, early disease diagnosis, image-guided surgery or photodynamic therapy.

Do you have any question ?
Feel free to contact us anytime.